IgA Nephropathy is one of the leading causes of kidney failure worldwide. It is caused by production of IgA1 antibodies lacking galactose in their o-Glycan regions, which cause them to be auto antigenic and can lead to protein aggregates. Traditional treatments have been limited to kidney care lifestyle modification and high-dose long term glucocordicosteroids. More recent experimental treatments include the anti-complement
drug Iptacopan, CD20 and CD38 based B cell depletion, and immunosuppressive APRIL/BAFF blockade.
Relavant Ancell Research Products
Human BAFF(CD257) related products
anti-human IgA mAb products
